Monitoring of Active Human Herpes Virus 6 Infection in Iranian Patients with Different Subtypes of Multiple Sclerosis

Table 1

Prevalence of HHV-6-DNA (copies/mL) and HHV-6-antibodies (U/mL) among controls and MS patients. HHV-6-DNA was analyzed in serum via qPCR as described previously. Concentration of plasma anti-HHV-6, IgG and IgM were measurement in an automated instrument, according to the manufacturer’s instructions. Data are representative of three independent experiments.

	Patients (𝑛=78)	Controls (𝑛=123)
	P (%)		Sig. (2-tailed)
	[mean ± SD]
Anti-IgG (U/mL)	61 (78.20); [15.54±1.90]	94 (76.42); [12.37±1.59]	P = NS
Anti-IgM (U/mL)	27 (34.61); [24.90±1.85]	8 (6.50); [26.97±2.10]	𝑃<0.05
Saliva-DNA (copies/mL)	9 (11.53); [127±11.00]	3 (2.43); [152±18.33]	𝑃<0.05
Serum-DNA (copies/mL)	47 (60.25); [264±51.51]	18 (14.63); [192±54.19]	𝑃<0.001
PBMCs-DNA (copies/mL)	52 (66.66); [165±41.38]	51 (41.46); [157±32.57]	𝑃<0.05

PBMCs: peripheral blood mononuclear cells; CSF: cerebrospinal fluid; P: positive; NS: not significant.